Segall Bryant & Hamill’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.52M Sell
25,747
-1,313
-5% -$80.2K 0.02% 508
2026
Q2
$1.54M Sell
27,060
-41
-0.2% -$1.82K 0.02% 497
2026
Q1
$805K Sell
27,101
-86
-0.3% -$2.57K 0.01% 530
2025
Q4
$1.04M Buy
+27,187
New +$884K 0.01% 503

Other funds holding TVTX

Segall Bryant & Hamill's TVTX Position: Q3 2026 in Review

Segall Bryant & Hamill reduced its Travere Therapeutics (TVTX) stake by 4.9% in Q3 2026, selling an estimated $80.2K and leaving 25,747 shares worth $1.52M. The position accounts for 0.02% of the portfolio, ranked #508.

Segall Bryant & Hamill first reported a position in TVTX in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.54M in Q2 2026. 345 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

  • Segall Bryant & Hamill held 25,747 shares of Travere Therapeutics worth $1.52M as of Q3 2026.
  • Segall Bryant & Hamill sold 1,313 Travere Therapeutics shares in Q3 2026, an estimated $80.2K.
  • Travere Therapeutics made up 0.02% of Segall Bryant & Hamill's portfolio in Q3 2026, its #508 holding.
  • Segall Bryant & Hamill first reported a position in Travere Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Segall Bryant & Hamill's Travere Therapeutics position peaked at $1.54M in Q2 2026.
  • 345 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on Segall Bryant & Hamill's 13F filing for Q3 2026, filed 16 Nov 2026.